Determinants and Machine Learning Prediction of Subtherapeutic Sodium Valproate Concentrations in Epilepsy Management in Xinjiang, China [0.03%]
Hao Yang,Xue Lv,Akbar Kadeer et al.
Hao Yang et al.
Background and objective: Valproic acid is a classic antiepileptic drug; however, it is characterized by a narrow therapeutic window, limited safety margin, and marked individual variability. Therapeutic drug monitoring h...
Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White Participants [0.03%]
Chi-Chi Peng,Eric Salgado,Jessica Corpus et al.
Chi-Chi Peng et al.
Background and objective: Obeldesivir is an orally administered prodrug of the nucleoside GS-441524. In vitro and preclinical studies have shown that obeldesivir can inhibit severe acute respiratory syndrome coronavirus 2...
Kinetics of Sevoflurane Vaporized Directly in Extracorporeal Membrane Oxygenators-Ex Vivo Findings and Pharmacokinetic/Pharmacodynamic Simulations [0.03%]
Diana Morales Castro,Mark Alm,Federico Carlos Carini et al.
Diana Morales Castro et al.
Background: Although sedation is commonly used in patients undergoing venovenous extracorporeal membrane oxygenation (V-V ECMO), the use of volatile anesthetics is less frequent, and there is limited data on the pharmacok...
Estimation of Plasma Meropenem Concentrations in Patients with Severe Infections Using Ultraviolet and Visible Range Spectrophotometry: A Pilot Study [0.03%]
Paul Skorup,Fredrik Sjövall,Fredrik Huss et al.
Paul Skorup et al.
Background and objective: Achieving adequate concentrations of beta-lactam antibiotics in patients with severe infections is challenging, and therefore therapeutic drug monitoring (TDM) would be optimal for guiding beta-l...
Evaluating Oxaliplatin Exposure in Adults with Advanced Colorectal Cancer: Development and Validation of Methods with Enhanced Bioanalytical Specificity and Clinical Applicability [0.03%]
John Ho,Catherine Han,Mark James McKeage
John Ho
Background and aims: The clinical efficacy and adverse effects of oxaliplatin [Pt(DACH)(oxalato)] (DACH = 1R,2R-cyclohexanediamine) may depend upon systemic drug exposure quantified as the area under the plasma concentrat...
Population Pharmacokinetics of Melphalan in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation with Various Conditioning Regimens [0.03%]
采用不同预处理方案行自体造血干细胞移植的儿童马法兰群体药代动力学分析
Jung Yoon Choi,Byungwook Kim,Hyun Jin Park et al.
Jung Yoon Choi et al.
Background and objective: Melphalan is an alkylating agent used in conditioning regimens for hematopoietic stem cell transplantation (HSCT) in pediatric patients. In this study, we aimed to develop a population pharmacoki...
Personalizing Liposomal Paclitaxel in Platinum-Based Combination Therapy for Gynecologic Cancers: Defining a Therapeutic Window Based on Tc>0.05 and CYP2C8 Metabolic Capacity [0.03%]
基于Tc>0.05和CYP2C8代谢能力的铂类联合疗法中个性化脂质体多西他赛治疗妇科肿瘤的剂量窗口研究
Shuai Jiang,Yao Yao,Dongqing Gao et al.
Shuai Jiang et al.
Background and objective: Current body surface area (BSA)-based dosing of liposomal paclitaxel (L-PTX) fails to account for substantial interpatient variability in drug exposure, leading to inconsistent therapeutic outcom...
Limited Sampling Strategies to Estimate the Exposition of Different Lipid Nanocaspules [0.03%]
有限取样策略估计不同脂质纳米胶囊暴露量的方法
Jean-Luc Cissé,Samuel Legeay,Vincent Lebreton
Jean-Luc Cissé
Background and objective: The use of nanoparticles in the field of drug delivery and the optimization of pharmacokinetic profiles in vivo is a growing area of research. The aim of this study is to determine the key sampli...
Drug-Drug Interactions in Recently Approved Antibacterials: A Mini Review [0.03%]
近年获批抗菌药物的药物相互作用——综述型文章
Isabella Baccari,Felix Bergmann,Markus Zeitlinger
Isabella Baccari
Drug-drug interactions (DDIs) pose an important concern in elderly and multimorbid patients receiving complex pharmacotherapy. The addition of antimicrobial therapy can increase DDI risk, potentially reducing therapeutic efficacy or increas...
Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal Women [0.03%]
绝经后妇女中费佐利纳坦的临床药代动力学、物质平衡和代谢研究
Megumi Iwai,Kinya Souda,Mayuko Miyagawa et al.
Megumi Iwai et al.
Background: Fezolinetant is a non-hormonal selective neurokinin-3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause. The objective of this study was to characterize t...